Valuation: Fortress Biotech, Inc.

Market Cap 91.68M 80.39M 74.1M 69.37M 130M 8.65B 133M 891M 345M 4.27B 344M 337M 14.82B P/E 2026 *
1.15x
P/E 2027 * 5.47x
Enterprise Value 91.68M 80.39M 74.1M 69.37M 130M 8.65B 133M 891M 345M 4.27B 344M 337M 14.82B EV / Sales 2026 *
1.15x
EV / Sales 2027 * 0.68x
Free-Float
77.21%
Yield 2026 *
-
Yield 2027 * -
1 day-8.61%
1 week-7.69%
Current month-1.43%
1 month+2.60%
3 months-4.17%
6 months-26.20%
Current year-24.59%
1 week 2.7
Extreme 2.7
3.35
1 month 2.53
Extreme 2.526
3.35
Current year 2.18
Extreme 2.18
4.53
1 year 1.75
Extreme 1.75
4.53
3 years 1.24
Extreme 1.24
10.35
5 years 1.24
Extreme 1.24
57.15
10 years 1.24
Extreme 1.24
91.5
Manager TitleAgeSince
Chief Executive Officer 71 20/12/2013
Director of Finance/CFO 51 22/02/2012
Director of Finance/CFO 36 16/08/2022
Director TitleAgeSince
Director/Board Member 74 01/12/2008
Chairman 71 20/12/2013
Director/Board Member 63 01/06/2006
Date Insider Type Main position Quantity % Market Cap.
22/06Free

Chief Financial Officer

400,000 1.2041%
01/04Free

Chief Financial Officer

2,967 0.0096%
18/03Free

Chief Executive Officer

475,424 1.5318%
Change 5-day change 1-year change 3-year change Capi.($)
-8.61%-7.69%+49.19%-67.72% 91.68M
+2.06%+3.76%+21.48%-19.31% 64.39B
+0.74%+3.52%+53.14%+219.37% 56.12B
-3.10%+34.30%+34.30%+34.30% 40.54B
-2.36%-1.25%-52.13%-58.98% 37.98B
+6.97%+9.89%+70.21%-23.28% 31.89B
+12.59%+5.18%+144.26%-44.13% 26.69B
+5.78%+15.81%+60.64%+80.73% 22.73B
-1.25%-1.31%-4.39%+142.42% 16.66B
-0.81%+5.91%+67.70%+124.13% 16.6B
Average +1.20%+3.12%+44.44%+38.75% 31.37B
Weighted average by Cap. +1.96%+4.10%+39.21%+46.41%

Financials

2026 *2027 *
Net sales 79.88M 70.04M 64.56M 60.44M 113M 7.53B 116M 776M 300M 3.72B 300M 293M 12.91B 134M 118M 108M 102M 190M 12.65B 194M 1.3B 504M 6.25B 504M 493M 21.69B
Net income 90.51M 79.36M 73.15M 68.49M 128M 8.54B 131M 879M 340M 4.22B 340M 332M 14.63B 21.13M 18.53M 17.08M 15.99M 29.98M 1.99B 30.6M 205M 79.43M 985M 79.35M 77.61M 3.42B
Net Debt - -
Logo Fortress Biotech, Inc.
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Employees
78
Date Price Change Volume
26/06/26 USD 2.760 -8.61% 1,103,740
25/06/26 USD 3.020 -3.82% 574,922
24/06/26 USD 3.140 -0.63% 898,517
23/06/26 USD 3.160 +2.60% 791,591
22/06/26 USD 3.080 +3.01% 538,154
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.760USD
Average target price
11.00USD
Spread / Average Target
+298.55%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBIO Stock